You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMibefradil
Accession NumberDB01388
TypeSmall Molecule
GroupsWithdrawn
DescriptionMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PosicorNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII27B90X776A
CAS number116644-53-2
WeightAverage: 495.6287
Monoisotopic: 495.289720302
Chemical FormulaC29H38FN3O3
InChI KeyInChIKey=HBNPJJILLOYFJU-VMPREFPWSA-N
InChI
InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
IUPAC Name
(1S,2S)-2-(2-{[3-(1H-1,3-benzodiazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
SMILES
COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassNot Available
Direct ParentTetralins
Alternative Parents
Substituents
  • Tetralin
  • Benzimidazole
  • Aralkylamine
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of angina and high blood pressure.
PharmacodynamicsMibefradil belongs to a group of medicines called calcium channel blocking agents, or, more commonly, calcium channel blockers. Calcium channel blocking agents affect the movement of calcium into the cells of the heart and blood vessels. As a result, they relax blood vessels and increase the supply of blood and oxygen to the heart while reducing its workload. Mibefradil is a benzimidazoyl-substituted tetraline that selectively binds and inhibits T-type calcium channels.
Mechanism of actionMibefradil is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Mibefradil causes a slight increase in cardiac output during chronic dosing. Mibefradil slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate–systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand.
Related Articles
AbsorptionBioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil.
Volume of distributionNot Available
Protein binding≥ 99%, primarily to alpha 1-acid glycoprotein.
Metabolism

The two metabolic pathways that mibefradil undergoes are esterase-catalyzed hydrolysis of the ester side chain (producing an alcohol metabolite) and cytochrome P450 3A4-catalyzed oxidation (that becomes less important during chronic dosing). The pharmacologic effect of the metabolite is approximately 10% of that of the parent mibefradil.

Route of eliminationNot Available
Half life17 to 25 hours at steady state.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.5
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.9087
P-glycoprotein inhibitor IInhibitor0.8718
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.549
CYP450 2C9 substrateNon-substrate0.8596
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6921
Ames testNon AMES toxic0.6864
CarcinogenicityNon-carcinogens0.892
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8610 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9611
hERG inhibition (predictor II)Inhibitor0.7742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
Caco2 permeability-4.87ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00104 mg/mLALOGPS
logP5.34ALOGPS
logP5.16ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)12.54ChemAxon
pKa (Strongest Basic)9.82ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.45 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity139.73 m3·mol-1ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC08CX01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Mibefradil.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Mibefradil.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Mibefradil.
AcebutololAcebutolol may increase the hypotensive activities of Mibefradil.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Mibefradil.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Mibefradil.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Mibefradil.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Mibefradil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Mibefradil.
AliskirenMibefradil may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Mibefradil.
AlprenololAlprenolol may increase the hypotensive activities of Mibefradil.
AmbrisentanMibefradil may increase the hypotensive activities of Ambrisentan.
AmifostineMibefradil may increase the hypotensive activities of Amifostine.
AmiodaroneThe metabolism of Mibefradil can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Mibefradil.
AmlodipineAmlodipine may increase the hypotensive activities of Mibefradil.
AmobarbitalThe metabolism of Mibefradil can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Mibefradil.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mibefradil.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Mibefradil.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Mibefradil.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mibefradil.
AprepitantThe serum concentration of Mibefradil can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Mibefradil.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Mibefradil.
AtazanavirThe metabolism of Mibefradil can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Mibefradil.
AtenololAtenolol may increase the hypotensive activities of Mibefradil.
AtomoxetineThe metabolism of Mibefradil can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Mibefradil is combined with Atosiban.
Atracurium besylateMibefradil may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Mibefradil.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Mibefradil.
BarbitalThe metabolism of Mibefradil can be increased when combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Mibefradil.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Mibefradil.
BenmoxinBenmoxin may increase the hypotensive activities of Mibefradil.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Mibefradil.
BepridilBepridil may increase the hypotensive activities of Mibefradil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Mibefradil.
BetaxololBetaxolol may increase the hypotensive activities of Mibefradil.
BethanidineBethanidine may increase the hypotensive activities of Mibefradil.
BexaroteneThe serum concentration of Mibefradil can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Mibefradil.
BimatoprostBimatoprost may increase the hypotensive activities of Mibefradil.
BisoprololBisoprolol may increase the hypotensive activities of Mibefradil.
BoceprevirThe metabolism of Mibefradil can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Mibefradil.
BortezomibThe metabolism of Mibefradil can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mibefradil can be decreased when it is combined with Bosentan.
BosentanMibefradil may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mibefradil.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mibefradil.
BretyliumBretylium may increase the hypotensive activities of Mibefradil.
BrimonidineMibefradil may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Mibefradil.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Mibefradil.
BupranololMibefradil may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Mibefradil.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Mibefradil.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Mibefradil.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Mibefradil.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Mibefradil.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Mibefradil.
CandesartanCandesartan may increase the hypotensive activities of Mibefradil.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Mibefradil.
CandoxatrilCandoxatril may increase the hypotensive activities of Mibefradil.
CaptoprilCaptopril may increase the hypotensive activities of Mibefradil.
CarbamazepineThe metabolism of Mibefradil can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Mibefradil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Mibefradil.
CaroxazoneCaroxazone may increase the hypotensive activities of Mibefradil.
CarteololCarteolol may increase the hypotensive activities of Mibefradil.
CarvedilolCarvedilol may increase the hypotensive activities of Mibefradil.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Mibefradil.
CeliprololMibefradil may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Mibefradil can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mibefradil.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Mibefradil.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Mibefradil.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Mibefradil.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mibefradil.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Mibefradil.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Mibefradil.
CilazaprilCilazapril may increase the hypotensive activities of Mibefradil.
CimetidineThe serum concentration of Mibefradil can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Mibefradil.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Mibefradil.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Mibefradil.
ClarithromycinThe metabolism of Mibefradil can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Mibefradil.
ClemastineThe metabolism of Mibefradil can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Mibefradil.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Mibefradil.
ClonidineClonidine may increase the hypotensive activities of Mibefradil.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Mibefradil.
ClotrimazoleThe metabolism of Mibefradil can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Mibefradil.
CobicistatThe metabolism of Mibefradil can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Mibefradil.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mibefradil.
ConivaptanThe serum concentration of Mibefradil can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mibefradil.
CrizotinibThe metabolism of Mibefradil can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Mibefradil.
CryptenamineCryptenamine may increase the hypotensive activities of Mibefradil.
CyclosporineThe metabolism of Mibefradil can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mibefradil.
CyclothiazideCyclothiazide may increase the hypotensive activities of Mibefradil.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mibefradil.
DabrafenibThe serum concentration of Mibefradil can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Mibefradil.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Mibefradil.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Mibefradil.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Mibefradil.
DarunavirThe metabolism of Mibefradil can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Mibefradil can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Mibefradil.
DebrisoquinMibefradil may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Mibefradil.
DeferasiroxThe serum concentration of Mibefradil can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Mibefradil can be decreased when combined with Delavirdine.
DeserpidineMibefradil may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Mibefradil can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Mibefradil.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Mibefradil.
DiazoxideDiazoxide may increase the hypotensive activities of Mibefradil.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mibefradil.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Mibefradil.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mibefradil.
DihydroergotamineThe metabolism of Mibefradil can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Mibefradil.
DiltiazemDiltiazem may increase the hypotensive activities of Mibefradil.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Mibefradil.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Mibefradil.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mibefradil.
DorzolamideDorzolamide may increase the hypotensive activities of Mibefradil.
DoxazosinDoxazosin may increase the hypotensive activities of Mibefradil.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mibefradil.
DoxycyclineThe metabolism of Mibefradil can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Mibefradil can be decreased when combined with Dronedarone.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Mibefradil.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Mibefradil.
EfavirenzThe serum concentration of Mibefradil can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Mibefradil.
EfonidipineMibefradil may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mibefradil.
EnalaprilEnalapril may increase the hypotensive activities of Mibefradil.
EnalaprilatMibefradil may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Mibefradil can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Mibefradil.
EpoprostenolEpoprostenol may increase the hypotensive activities of Mibefradil.
EprosartanEprosartan may increase the hypotensive activities of Mibefradil.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Mibefradil.
ErythromycinThe metabolism of Mibefradil can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Mibefradil.
Eslicarbazepine acetateThe serum concentration of Mibefradil can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Mibefradil.
EstriolThe serum concentration of Estriol can be increased when it is combined with Mibefradil.
EstroneThe serum concentration of Estrone can be increased when it is combined with Mibefradil.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mibefradil.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Mibefradil.
EtravirineThe serum concentration of Mibefradil can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mibefradil.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Mibefradil.
FelodipineFelodipine may increase the hypotensive activities of Mibefradil.
FenoldopamFenoldopam may increase the hypotensive activities of Mibefradil.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mibefradil.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Mibefradil.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Mibefradil.
FluconazoleThe serum concentration of Mibefradil can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Mibefradil.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Mibefradil.
FluvoxamineThe metabolism of Mibefradil can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Mibefradil can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mibefradil can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Mibefradil.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Mibefradil.
FosphenytoinThe metabolism of Mibefradil can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Mibefradil.
Fusidic AcidThe serum concentration of Mibefradil can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Mibefradil.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Mibefradil.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Mibefradil.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Mibefradil.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Mibefradil.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Mibefradil.
GuanabenzGuanabenz may increase the hypotensive activities of Mibefradil.
GuanadrelGuanadrel may increase the hypotensive activities of Mibefradil.
GuanethidineGuanethidine may increase the hypotensive activities of Mibefradil.
GuanfacineGuanfacine may increase the hypotensive activities of Mibefradil.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Mibefradil.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Mibefradil.
HexamethoniumMibefradil may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Mibefradil.
HexobarbitalThe metabolism of Mibefradil can be increased when combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Mibefradil.
HydralazineHydralazine may increase the hypotensive activities of Mibefradil.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Mibefradil.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mibefradil.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Mibefradil.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Mibefradil.
IdelalisibThe serum concentration of Mibefradil can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Mibefradil.
ImatinibThe metabolism of Mibefradil can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mibefradil.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Mibefradil.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Mibefradil.
IndapamideIndapamide may increase the hypotensive activities of Mibefradil.
IndenololMibefradil may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Mibefradil can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Mibefradil.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Mibefradil.
IndoraminMibefradil may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Mibefradil.
IproniazidIproniazid may increase the hypotensive activities of Mibefradil.
IrbesartanIrbesartan may increase the hypotensive activities of Mibefradil.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Mibefradil.
IsavuconazoniumThe metabolism of Mibefradil can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Mibefradil.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Mibefradil.
IsradipineIsradipine may increase the hypotensive activities of Mibefradil.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Mibefradil.
IvacaftorThe serum concentration of Mibefradil can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Mibefradil.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Mibefradil.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Mibefradil.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Mibefradil.
LabetalolLabetalol may increase the hypotensive activities of Mibefradil.
LacidipineMibefradil may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Mibefradil.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Mibefradil.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Mibefradil.
LatanoprostLatanoprost may increase the hypotensive activities of Mibefradil.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Mibefradil.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Mibefradil.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Mibefradil.
LercanidipineLercanidipine may increase the hypotensive activities of Mibefradil.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Mibefradil.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Mibefradil.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Mibefradil.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Mibefradil.
LisinoprilLisinopril may increase the hypotensive activities of Mibefradil.
LofexidineMibefradil may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Mibefradil.
LopinavirThe metabolism of Mibefradil can be decreased when combined with Lopinavir.
LosartanLosartan may increase the hypotensive activities of Mibefradil.
LovastatinThe metabolism of Mibefradil can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Mibefradil can be increased when it is combined with Luliconazole.
MacitentanMibefradil may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium Sulfate.
ManidipineMibefradil may increase the hypotensive activities of Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Mibefradil.
MebanazineMebanazine may increase the hypotensive activities of Mibefradil.
MecamylamineMecamylamine may increase the hypotensive activities of Mibefradil.
MethohexitalThe metabolism of Mibefradil can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mibefradil.
MethyldopaMethyldopa may increase the hypotensive activities of Mibefradil.
Methylene blueMethylene blue may increase the hypotensive activities of Mibefradil.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Mibefradil.
MethylphenobarbitalThe metabolism of Mibefradil can be increased when combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Mibefradil.
MetipranololMetipranolol may increase the hypotensive activities of Mibefradil.
MetolazoneMetolazone may increase the hypotensive activities of Mibefradil.
MetoprololMetoprolol may increase the hypotensive activities of Mibefradil.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Mibefradil.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Mibefradil.
MifepristoneThe metabolism of Mibefradil can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Mibefradil.
MinoxidilMinoxidil may increase the hypotensive activities of Mibefradil.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Mibefradil.
MitotaneThe serum concentration of Mibefradil can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Mibefradil.
MivacuriumMibefradil may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Mibefradil.
ModafinilThe serum concentration of Mibefradil can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Mibefradil.
MolsidomineMolsidomine may increase the hypotensive activities of Mibefradil.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Mibefradil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Mibefradil.
MoxonidineMibefradil may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mibefradil.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Mibefradil.
NadololNadolol may increase the hypotensive activities of Mibefradil.
NafcillinThe serum concentration of Mibefradil can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mibefradil.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mibefradil.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Mibefradil.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Mibefradil.
NebivololMibefradil may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Mibefradil can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Mibefradil can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Mibefradil.
NetupitantThe serum concentration of Mibefradil can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Mibefradil can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Mibefradil.
NicardipineNicardipine may increase the hypotensive activities of Mibefradil.
NicorandilMibefradil may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Mibefradil.
NiguldipineMibefradil may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Mibefradil can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Mibefradil.
NilvadipineMibefradil may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Mibefradil.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Mibefradil.
NisoldipineNisoldipine may increase the hypotensive activities of Mibefradil.
NitrendipineNitrendipine may increase the hypotensive activities of Mibefradil.
NitroprussideMibefradil may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Mibefradil.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Mibefradil.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Mibefradil.
ObinutuzumabMibefradil may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Mibefradil.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Mibefradil.
OlaparibThe metabolism of Mibefradil can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Mibefradil.
OmapatrilatOmapatrilat may increase the hypotensive activities of Mibefradil.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Mibefradil.
OsimertinibThe serum concentration of Mibefradil can be increased when it is combined with Osimertinib.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Mibefradil.
OxprenololMibefradil may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Mibefradil.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Mibefradil.
PalbociclibThe serum concentration of Mibefradil can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Mibefradil.
PargylineMibefradil may increase the hypotensive activities of Pargyline.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mibefradil.
PenbutololPenbutolol may increase the hypotensive activities of Mibefradil.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Mibefradil.
PentobarbitalThe metabolism of Mibefradil can be increased when combined with Pentobarbital.
PentoliniumPentolinium may increase the hypotensive activities of Mibefradil.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Mibefradil.
PerindoprilPerindopril may increase the hypotensive activities of Mibefradil.
PhenelzinePhenelzine may increase the hypotensive activities of Mibefradil.
PheniprazinePheniprazine may increase the hypotensive activities of Mibefradil.
PhenobarbitalThe metabolism of Mibefradil can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Mibefradil.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Mibefradil.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Mibefradil.
PhentolaminePhentolamine may increase the hypotensive activities of Mibefradil.
PhenytoinThe metabolism of Mibefradil can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Mibefradil.
PinacidilMibefradil may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Mibefradil.
PirlindolePirlindole may increase the hypotensive activities of Mibefradil.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mibefradil.
PivhydrazinePivhydrazine may increase the hypotensive activities of Mibefradil.
PolythiazidePolythiazide may increase the hypotensive activities of Mibefradil.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Mibefradil.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Mibefradil.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Mibefradil.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mibefradil.
PrazosinPrazosin may increase the hypotensive activities of Mibefradil.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Mibefradil.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Mibefradil.
PrimidoneThe metabolism of Mibefradil can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Mibefradil.
PropranololPropranolol may increase the hypotensive activities of Mibefradil.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mibefradil.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Mibefradil.
QuinaprilQuinapril may increase the hypotensive activities of Mibefradil.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Mibefradil.
QuinineQuinine may increase the hypotensive activities of Mibefradil.
QuinineThe serum concentration of Quinine can be increased when it is combined with Mibefradil.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Mibefradil.
RamiprilRamipril may increase the hypotensive activities of Mibefradil.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Mibefradil.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mibefradil.
RanolazineThe metabolism of Mibefradil can be decreased when combined with Ranolazine.
RapacuroniumMibefradil may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Mibefradil.
RemikirenRemikiren may increase the hypotensive activities of Mibefradil.
RescinnamineMibefradil may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Mibefradil.
RifabutinThe metabolism of Mibefradil can be increased when combined with Rifabutin.
RifampicinThe metabolism of Mibefradil can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Mibefradil.
RifapentineThe metabolism of Mibefradil can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mibefradil.
RiociguatMibefradil may increase the hypotensive activities of Riociguat.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Mibefradil.
RitonavirThe metabolism of Mibefradil can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Mibefradil.
RituximabMibefradil may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Mibefradil.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Mibefradil.
SafrazineSafrazine may increase the hypotensive activities of Mibefradil.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Mibefradil.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mibefradil.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Mibefradil.
SaprisartanSaprisartan may increase the hypotensive activities of Mibefradil.
SaquinavirThe metabolism of Mibefradil can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Mibefradil.
SecobarbitalThe metabolism of Mibefradil can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Mibefradil.
SelexipagMibefradil may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Mibefradil.
SildenafilSildenafil may increase the antihypertensive activities of Mibefradil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mibefradil.
SilodosinSilodosin may increase the hypotensive activities of Mibefradil.
SiltuximabThe serum concentration of Mibefradil can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mibefradil can be increased when it is combined with Simeprevir.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Mibefradil.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Mibefradil.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Mibefradil.
SitaxentanMibefradil may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Mibefradil.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Mibefradil.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Mibefradil.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Mibefradil.
SpiraprilSpirapril may increase the hypotensive activities of Mibefradil.
St. John's WortThe serum concentration of Mibefradil can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mibefradil can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Mibefradil.
SulfisoxazoleThe metabolism of Mibefradil can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Mibefradil.
TadalafilTadalafil may increase the antihypertensive activities of Mibefradil.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Mibefradil.
TamsulosinTamsulosin may increase the hypotensive activities of Mibefradil.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Mibefradil.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Mibefradil.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Mibefradil.
TelaprevirThe metabolism of Mibefradil can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Mibefradil.
TelithromycinThe metabolism of Mibefradil can be decreased when combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Mibefradil.
TemocaprilMibefradil may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Mibefradil.
TerazosinTerazosin may increase the hypotensive activities of Mibefradil.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Mibefradil.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Mibefradil.
TerlipressinMibefradil may increase the hypotensive activities of Terlipressin.
ThiamylalThe metabolism of Mibefradil can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Mibefradil can be increased when combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mibefradil.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Mibefradil.
TiboloneMibefradil may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Mibefradil.
TiclopidineThe metabolism of Mibefradil can be decreased when combined with Ticlopidine.
TicrynafenMibefradil may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Mibefradil.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Mibefradil.
TocilizumabThe serum concentration of Mibefradil can be decreased when it is combined with Tocilizumab.
TolazolineTolazoline may increase the hypotensive activities of Mibefradil.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Mibefradil.
ToloxatoneToloxatone may increase the hypotensive activities of Mibefradil.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mibefradil.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mibefradil.
TorasemideTorasemide may increase the hypotensive activities of Mibefradil.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Mibefradil.
TrandolaprilTrandolapril may increase the hypotensive activities of Mibefradil.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mibefradil.
TranylcypromineTranylcypromine may increase the hypotensive activities of Mibefradil.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Mibefradil.
TravoprostTravoprost may increase the hypotensive activities of Mibefradil.
TreprostinilTreprostinil may increase the hypotensive activities of Mibefradil.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Mibefradil.
TrimazosinMibefradil may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Mibefradil.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Mibefradil.
UdenafilUdenafil may increase the antihypertensive activities of Mibefradil.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mibefradil.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Mibefradil.
UnoprostoneMibefradil may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Mibefradil.
VardenafilVardenafil may increase the antihypertensive activities of Mibefradil.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Mibefradil.
VenlafaxineThe metabolism of Mibefradil can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Mibefradil.
VerapamilThe metabolism of Mibefradil can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Mibefradil.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Mibefradil.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mibefradil.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Mibefradil.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Mibefradil.
XylometazolineMibefradil may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Mibefradil.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Mibefradil.
ZiprasidoneThe metabolism of Mibefradil can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  3. Monteil A, Chemin J, Bourinet E, Mennessier G, Lory P, Nargeot J: Molecular and functional properties of the human alpha(1G) subunit that forms T-type calcium channels. J Biol Chem. 2000 Mar 3;275(9):6090-100. [PubMed:10692398 ]
  4. Massie BM: Mibefradil: a selective T-type calcium antagonist. Am J Cardiol. 1997 Nov 6;80(9A):23I-32I. [PubMed:9375939 ]
  5. Clozel JP, Ertel EA, Ertel SI: Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl. 1997 Dec;15(5):S17-25. [PubMed:9481612 ]
  6. McNulty MM, Hanck DA: State-dependent mibefradil block of Na+ channels. Mol Pharmacol. 2004 Dec;66(6):1652-61. [PubMed:15562257 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Brueggemann LI, Martin BL, Barakat J, Byron KL, Cribbs LL: Low voltage-activated calcium channels in vascular smooth muscle: T-type channels and AVP-stimulated calcium spiking. Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H923-35. Epub 2004 Oct 21. [PubMed:15498818 ]
  2. Coste B, Crest M, Delmas P: Pharmacological dissection and distribution of NaN/Nav1.9, T-type Ca2+ currents, and mechanically activated cation currents in different populations of DRG neurons. J Gen Physiol. 2007 Jan;129(1):57-77. [PubMed:17190903 ]
  3. Cribbs LL, Lee JH, Yang J, Satin J, Zhang Y, Daud A, Barclay J, Williamson MP, Fox M, Rees M, Perez-Reyes E: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Circ Res. 1998 Jul 13;83(1):103-9. [PubMed:9670923 ]
  4. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  5. Perez-Reyes E: Paradoxical role of T-type calcium channels in coronary smooth muscle. Mol Interv. 2004 Feb;4(1):16-8. [PubMed:14993472 ]
  6. Massie BM: Mibefradil: a selective T-type calcium antagonist. Am J Cardiol. 1997 Nov 6;80(9A):23I-32I. [PubMed:9375939 ]
  7. Clozel JP, Ertel EA, Ertel SI: Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl. 1997 Dec;15(5):S17-25. [PubMed:9481612 ]
  8. McNulty MM, Hanck DA: State-dependent mibefradil block of Na+ channels. Mol Pharmacol. 2004 Dec;66(6):1652-61. [PubMed:15562257 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Moosmang S, Haider N, Bruderl B, Welling A, Hofmann F: Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ Res. 2006 Jan 6;98(1):105-10. Epub 2005 Nov 23. [PubMed:16306443 ]
  2. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  3. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  4. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  2. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
  3. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  2. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
  3. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the "low-volta...
Gene Name:
CACNA1I
Uniprot ID:
Q9P0X4
Molecular Weight:
245100.8 Da
References
  1. Massie BM: Mibefradil: a selective T-type calcium antagonist. Am J Cardiol. 1997 Nov 6;80(9A):23I-32I. [PubMed:9375939 ]
  2. Clozel JP, Ertel EA, Ertel SI: Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl. 1997 Dec;15(5):S17-25. [PubMed:9481612 ]
  3. McNulty MM, Hanck DA: State-dependent mibefradil block of Na+ channels. Mol Pharmacol. 2004 Dec;66(6):1652-61. [PubMed:15562257 ]
  4. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  2. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
  3. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  2. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  3. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  2. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  3. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB3
Uniprot ID:
P54284
Molecular Weight:
54531.425 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  2. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  3. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB4
Uniprot ID:
O00305
Molecular Weight:
58168.625 Da
References
  1. Lee TS, Kaku T, Takebayashi S, Uchino T, Miyamoto S, Hadama T, Perez-Reyes E, Ono K: Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. Epub 2006 Aug 7. [PubMed:16899990 ]
  2. Mocanu MM, Gadgil S, Yellon DM, Baxter GF: Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovasc Drugs Ther. 1999 Apr;13(2):115-22. [PubMed:10372226 ]
  3. Jimenez C, Bourinet E, Leuranguer V, Richard S, Snutch TP, Nargeot J: Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. [PubMed:10665814 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wandel C, Kim RB, Guengerich FP, Wood AJ: Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos. 2000 Aug;28(8):895-8. [PubMed:10901697 ]
  2. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 14:41 / Updated on August 17, 2016 12:23